Biomedical Engineering Reference
In-Depth Information
106. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue,
M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan,
V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Röhl, I., Toudjarska,
I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S.,
Manoharan, M. and Vornlocher, H. P. (2004). Therapeutic silencing of
an endogenous gene by systemic administration of modified siRNAs.
Nature,
432,
pp. 173-178.
107. Stockman, L. J., Bellamy, R. and Garner, P. (2006). SARS: systematic
review of treatment eff ects.
PLoS Med,
3,
p. e343.
108. Subramanya, S., Kim, S. S., Abraham, S., Yao, J., Kumar, M., Kumar, P.,
Haridas, V., Lee, S. K., Shultz, L. D., Greiner, D., N, M. and Shankar, P. (2010).
Targeted delivery of small interfering RNA to human dendritic cells
to suppress dengue virus infection and associated proinflammatory
cytokine production.
J Virol,
84,
pp. 2490-2501.
109. Teng, M. N., Whitehead, S. S., Bermingham, A., St Claire, M., Elkins, W.
R., Murphy, B. R. and Collins, P. L. (2000). Recombinant respiratory
syncytial virus that does not express the NS1 or M2-2 protein is highly
attenuated and immunogenic in chimpanzees.
J Virol,
74,
pp. 9317-
9321.
110. Tompkins, S. M., Lo, C. Y., Tumpey, T. M. and Epstein, S. L. (2004).
Protection against lethal influenza virus challenge by RNA interference
in vivo
.
Proc Natl Acad Sci U S A,
101,
pp. 8682-8686.
111. Travanty, E. A., Adelman, Z. N., Franz, A. W., Keene, K. M., Beaty, B. J.,
Blair, C. D., James, A. A. and Olson, K. E. (2004). Using RNA interference
to develop dengue virus resistance in genetically modified Aedes
aegypti.
Insect Biochem Mol Biol,
34,
pp. 607-613.
112. Uprichard, S. L., Boyd, B., Althage, A. and Chisari, F. V. (2005). Clearance
of hepatitis B virus from the liver of transgenic mice by short hairpin
RNAs.
Proc Natl Acad Sci U S A,
102,
pp. 773-778.
113. Virxsys Corporation (2009). HIV RNA Therapy. Available from: http://
www.virxsys.com/pages/human-therapies/hiv-rna-therapy.php.
114. Wang, M. D. and Jolly, A. M. (2004). Changing virulence of the SARS
virus: the epidemiological evidence.
Bull World Health Organ,
82,
pp.
547-548.
115. Warfield, K. L., Swenson, D. L., Olinger, G. G., Nichols, D. K., Pratt, W. D.,
Blouch, R., Stein, D. A., Aman, M. J., Iversen, P. L. and Bavari, S. (2006).
Gene-specific countermeasures against Ebola virus based on antisense
phosphorodiamidate morpholino oligomers.
PLoS Pathog,
2,
p. e1.
116. Wen, W. H., Liu, J. Y., Qin, W. J., Zhao, J., Wang, T., Jia, L. T., Meng, Y. L.,
Gao, H., Xue, C. F., Jin, B. Q., Yao, L. B., Chen, S. Y. and Yang, A. G. (2007).
Targeted inhibition of HBV gene expression by single-chain antibody
mediated small interfering RNA delivery.
Hepatology,
46,
pp. 84-94.
Search WWH ::
Custom Search